{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:43:41Z","timestamp":1784004221581,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T00:00:00Z","timestamp":1392854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00393-013-1307-6","type":"journal-article","created":{"date-parts":[[2014,2,18]],"date-time":"2014-02-18T09:27:24Z","timestamp":1392715644000},"page":"650-656","source":"Crossref","is-referenced-by-count":10,"title":["Etanercept therapy in Beh\u00e7et\u2019s disease","Etanercepttherapie bei M.\u00a0Beh\u00e7et"],"prefix":"10.1007","volume":"73","author":[{"given":"R.H.A.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,20]]},"reference":[{"key":"1307_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2474-4-19","volume":"4","author":"Gulli","year":"2003","unstructured":"Gulli S, Arrigo C, Bocchino L et al (2003) Remission of Behcet\u2019s disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 4:19","journal-title":"BMC Musculoskelet Disord"},{"key":"1307_CR2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N et al (1999) Behcet\u2019s disease. N Engl J Med 341:1284\u20131291","journal-title":"N Engl J Med"},{"key":"1307_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","volume":"31","author":"Hamzaoui","year":"2002","unstructured":"Hamzaoui K, Hamzaoui A, Guemira F et al (2002) Cytokine profile in Behcet\u2019s disease patients. Relationship with disease activity. Scand J Rheumatol 31:205\u2013210","journal-title":"Scand J Rheumatol"},{"key":"1307_CR4","first-page":"249","volume":"18","author":"Mantas","year":"2000","unstructured":"Mantas C, Direskeneli H, Oz D et al (2000) IL-8 producing cells in patients with Behcet\u2019s disease. Clin Exp Rheumatol 18:249\u2013251","journal-title":"Clin Exp Rheumatol"},{"key":"1307_CR5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1365-2249.1997.3611265.x","volume":"108","author":"Kaneko","year":"1997","unstructured":"Kaneko S, Suzuki N, Yamashita N et al (1997) Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet\u2019s disease (BD) in Japan. Clin Exp Immunol 108:204\u2013212","journal-title":"Clin Exp Immunol"},{"key":"1307_CR6","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.4049\/jimmunol.165.10.5814","volume":"165","author":"Witowski","year":"2000","unstructured":"Witowski J, Pawlaczyk K, Breborowicz A et al (2000) IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 165:5814\u20135821","journal-title":"J Immunol"},{"key":"1307_CR7","first-page":"128","volume":"24","author":"Turan","year":"1997","unstructured":"Turan B, Gallati H, Erdi H et al (1997) Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet\u2019s disease: soluble TNFR-75 as a biologic marker of disease activity. J Rheumatol 24:128\u2013132","journal-title":"J Rheumatol"},{"key":"1307_CR8","first-page":"S6","volume":"19","author":"Gul","year":"2001","unstructured":"Gul A (2001) Behcet\u2019s disease: an update on the pathogenesis. Clin Exp Rheumatol 19(Suppl):S6\u2013S12","journal-title":"Clin Exp Rheumatol"},{"key":"1307_CR9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2249.1997.274-ce1159.x","volume":"107","author":"Yamashita","year":"1997","unstructured":"Yamashita N, Kaneoka H, Kaneko S et al (1997) Role of gammadelta T lymphocytes in the development of Beh\u00e7et\u2019s disease. Clin Exp Immunol 107(2):241\u2013247","journal-title":"Clin Exp Immunol"},{"key":"1307_CR10","first-page":"687","volume":"13","author":"Emmi","year":"1995","unstructured":"Emmi L, Brugnolo F, Salvati G et al (1995) Immunopathological aspects of Behcet\u2019s disease. Clin Exp Rheumatol 13:687\u2013691","journal-title":"Clin Exp Rheumatol"},{"key":"1307_CR11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatic arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932\u20131939","journal-title":"Lancet"},{"key":"1307_CR12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/sarh.2001.19819","volume":"30","author":"Kaklamani","year":"2001","unstructured":"Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet\u2019s disease: an update. Semin Arthritis Rheum 30:299\u2013312","journal-title":"Semin Arthritis Rheum"},{"key":"1307_CR13","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1136\/ard.61.suppl_2.ii51","volume":"61","author":"Sfikakis","year":"2002","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2002) Behcet\u2019s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl II):S51\u2013S53","journal-title":"Ann Rheum Dis"},{"key":"1307_CR14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/ard.60.6.637","volume":"60","author":"Goossens","year":"2001","unstructured":"Goossens PH, Verburg RJ, Breedveld FC (2001) Remission of Behcet\u2019s syndrome with tumour necrosis factor a blocking therapy. Ann Rheum Dis 60:637","journal-title":"Ann Rheum Dis"},{"key":"1307_CR15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","volume":"18","author":"Imrie","year":"2007","unstructured":"Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18:481\u2013486","journal-title":"Curr Opin Ophthalmol"},{"key":"1307_CR16","first-page":"1078","volume":"335","author":"n","year":"1990","unstructured":"n A (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. International Study Group for Beh\u00e7et\u2019s Disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"1307_CR17","first-page":"671","volume":"87","author":"Luqmani","year":"1994","unstructured":"Luqmani RA, Bacon PA, Moots RJ et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87(11):671\u2013678","journal-title":"QJM"},{"key":"1307_CR18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/archopht.1982.01030040433013","volume":"100","author":"Ohno","year":"1982","unstructured":"Ohno S, Ohguchi M, Hirose S et al (1982) Close association of HLA-Bw51 with Behcet\u2019s disease. Arch Ophthalmol 100:1455\u20131458","journal-title":"Arch Ophthalmol"},{"key":"1307_CR19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","volume":"18","author":"Bawazeer","year":"2010","unstructured":"Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Beh\u00e7et disease. Ocul Immunol Inflamm 18(3):226\u2013232","journal-title":"Ocul Immunol Inflamm"},{"key":"1307_CR20","first-page":"82","volume":"31","author":"Alokaily","year":"2010","unstructured":"Alokaily F, Alsaleh S, Al-Balawi M et al (2010) Efficacy of infliximab on the acute attack of uveitis. Saudi Med J 31(1):82\u201385","journal-title":"Saudi Med J"},{"key":"1307_CR21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E et al (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Sem Arthritis Rheum 41:61","journal-title":"Sem Arthritis Rheum"},{"key":"1307_CR22","first-page":"98","volume":"32","author":"Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study. J Rheumatol 32(1):98\u2013105","journal-title":"J Rheumatol"},{"key":"1307_CR23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","volume":"146","author":"Tabbara","year":"2008","unstructured":"Tabbara KF, Al-Hemidan AI (2008) Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease. Am J Ophthalmol 146(6):845\u2013850","journal-title":"Am J Ophthalmol"},{"key":"1307_CR24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","volume":"29","author":"Al-Rayes","year":"2008","unstructured":"Al-Rayes H, Al-Swailem R, Al-Balawi M et al (2008) Safety and efficacy of infliximab therapy in active Behcet\u2019s uveitis: an open-label trial. Rheumatol Int 29(1):53\u201357","journal-title":"Rheumatol Int"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-013-1307-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1307-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:36:17Z","timestamp":1559046977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-013-1307-6"}},"subtitle":["The tight control strategy in refractory disease","Engmaschige Kontrolle bei therapierefrakt\u00e4rer Erkrankung"],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["1307"],"URL":"https:\/\/doi.org\/10.1007\/s00393-013-1307-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}